Metastatic bone disease: A 36-Year single centre trend-analysis of patients admitted to a tertiary orthopaedic surgical department

• Published in: Journal of surgical oncology 2007-10, Vol.96 (5), p.404-410
• Main Authors: Toma, C.D., Dominkus, M., Nedelcu, T., Abdolvahab, F., Assadian, O., Krepler, P., Kotz, R.
• Format: Article
• Language: English
• Subjects: Adult; Age Distribution; Aged; Aged, 80 and over; Austria - epidemiology; Bone and Bones - pathology; bone metastasis; Bone Neoplasms - epidemiology; Bone Neoplasms - secondary; Bone Neoplasms - therapy; Breast Neoplasms - epidemiology; Breast Neoplasms - pathology; Carcinoma, Renal Cell - epidemiology; Carcinoma, Renal Cell - pathology; Combined Modality Therapy; Female; Humans; Kidney Neoplasms - epidemiology; Kidney Neoplasms - pathology; Male; Middle Aged; outcome; Registries; Retrospective Studies; Sex Distribution; survival
• ISSN: 0022-4790; 1096-9098
• DOI: 10.1002/jso.20787

Background and Objectives The treatment and outcome of primary malignant bone tumours has changed with the advances in diagnostic and treatment modalities. A trend‐analysis on a large cohort of patients with metastatic bone disease was performed. Methods A retrospective chart review of all cases with metastatic bone disease admitted to a single tertiary orthopaedic referral centre, registered with the Vienna Bone and Soft Tissue Tumour Registry between 1968 and 2003 was conducted. For trend‐analysis of frequency, survival, primary site, treatment methods, and others, the 36‐year study duration was divided into four periods. Results The study identified 601 females and 580 males (mean: 60 years) with metastatic bone disease. The most common metastases were secondary to breast cancer (n = 275; 23%) and renal cell carcinoma (n = 242; 21%) and the majority were located in the femur (n = 332; 28%) and spine (n = 348; 29%). Overall, the proportion of patients who underwent surgery decreased. At follow‐up, 887 (75%) patients were verified to have died of their disease. Conclusions Over the 36‐year period, the frequency of bone metastases has increased at our centre. Although survival increased over time, the difference was not significant; this was most likely attributable to the seriousness of cases referred to our tertiary care centre. J. Surg. Oncol. 2007;96:404–410. © 2007 Wiley‐Liss, Inc.